Hematologic Oncology

Jonathon B. Cohen MD, MS, discusses the management of chronic lymphocytic leukemia with BTK inhibitors, updates in the treatment of acute myeloid leukemia, and how CAR T-cell therapy could improve patient outcomes in diffuse large B-cell lymphoma and mantle cell lymphoma.

Treatment with ibrutinib for at least 5 years showed favorable complete response rates and tolerability in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma who were randomized to receive the BTK inhibitor in the phase 3 RESONATE-2 trial.

Fixed-duration treatment with ibrutinib and venetoclax led to deeper and prolonged undetectable minimal residual disease responses vs chlorambucil and obinutuzumab in the frontline treatment of elderly or unfit patients with chronic lymphocytic leukemia, translating to fewer relapses in the first year following treatment cessation.

Gilteritinib, in combination with induction and consolidation chemotherapy, generated responses in patients with newly diagnosed acute myeloid leukemia, including those with FLT3 mutations, according to data from a phase 1 trial.

Ivosidenib plus venetoclax with or without azacitidine showed an expected and tolerable safety profile with durable responses and a prolonged survival rate across acute myeloid leukemia disease groups.

Oral decitabine plus cedazuridine added to oral venetoclax demonstrated promising overall response rates in patients with acute myeloid leukemia who received the combination as a first-line treatment or after relapsing on prior therapies.

Zanubrutinib elicited significantly higher response rates and survival benefits compared with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma .

Loncastuximab tesirine-lpyl combined with rituximab demonstrated encouraging antitumor activity and a feasible safety profile in patients with relapsed/refractory diffuse large B-cell lymphoma.

Momelotinib induced superior 24-week overall survival rates compared with danazol in thrombocytopenic, symptomatic, and anemic patients with myelofibrosis.

Ivosidenib plus azacitidine displayed favorable event-free survival, overall survival, and clinical responses compared with placebo plus azacitidine in patients with newly diagnosed, IDH1-mutated acute myeloid leukemia, according to findings from the phase 3 AGILE study.

The Japan Ministry of Health, Labor and Welfare has approved valemetostat tosilate for the treatment of patients with relapsed or refractory adult T-cell leukemia/lymphoma.

In an 8 to 4 vote, the FDA’s Oncologic Drugs Advisory Committee voted that the final overall survival data submitted did not demonstrate a strong enough benefit-risk ratio for duvelisib for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma after at least 2 prior therapies.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of zanubrutinib for use in adult patients with marginal zone lymphoma who have received at least 1 prior anti–CD20-based therapy.

The European Medicines Agency Committee for Medicinal Products for Human Use has granted a positive opinion for axicabtagene ciloleucel for the treatment of adult patients with diffuse large B-cell lymphoma and high-grade B-cell lymphoma who relapse within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.

Andre H. Goy, MD, discusses updates in precision medicine.

James K. McCloskey, MD, discusses the efficacy of CPX-351 in FLT3-mutated acute myeloid leukemia.

Abhinav Deol, MD, discusses how Karmanos Cancer Institute prepares trainees for their first job and helps them handle negative situations and deal with grief.

Srdan Verstovsek, MD, PhD, discusses the FDA approval of pemigatinib, an FGFR1 inhibitor, in patients with myeloid neoplasms with an FGFR1 rearrangement.

Srdan Verstovsek, MD, PhD, discusses the clinical implications of the FDA approval of pemigatinib, the results of the FIGHT-203 trial, and the need to conduct chromosomal analysis for patients with myeloid/lymphoid neoplasms.

Results from a retrospective analysis presented during the 2022 ESMO Congress indicated that circulating tumor DNA could potentially be leveraged as a prognostic factor and a tumor-specific biomarker for diffuse large B-cell lymphoma in China.

The combination of orelabrutinib and R-CHOP elicited a favorable overall response rate and progression-free response rate in patients with previously untreated non–germinal center B-cell–like diffuse large B-cell lymphoma (DLBCL) with extranodal disease.

Saul A. Rosenberg, MD, FASCO, the Maureen Lyles D’Ambrogio Professor Emeritus at Stanford School of Medicine and the 2019 Giants of Cancer Care® award winner for Lymphoma, died at the age of 95.

Azacitidine plus venetoclax showed encouraging activity in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukemia.

Dr Chen details the findings from a study of patients with transformed cutaneous T-cell lymphoma, gives her perspective on findings from the FLASH trial, and discusses the need for more research funding in this disease.

The European Commission has granted an orphan drug designation to nanatinostat and valganciclovir for use as a potential therapeutic option in patients with peripheral T-cell lymphoma.

Emavusertib elicited antitumor activity when given as a monotherapy in patients with relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndrome that harbored a spliceosome or FLT3 mutation.

A single-center study at the Dana-Farber Cancer Institute/Brigham and Women’s Hospital assessed the real-world experience of 20 patients treated with idecabtagene vicleucel with relapsed and refractory multiple myeloma who had exhausted at least 4 lines of prior therapy.

Five years since the first FDA approval of CAR T-cell therapy in relapsed/refractory lymphoma, there is still much to learn about how to optimize its use, according to Sattva S. Neelapu, MD.

Findings of a retrospective study demonstrated a high dosing compliance with daratumumab compared with approved indications for patients with multiple myeloma in the real-world setting.

Fixed-duration bendamustine plus rituximab was effective in patients with previously untreated Waldenström macroglobulinemia, regardless of MYD88L265P mutation status, but the presence of the CXCR4WHIM mutation may be associated with resistance to the combination.